BPC-157 is a synthetic 15 amino acid peptide derived from a protein called BPC — Body Protection Compound — first isolated from human gastric juice in the early 1990s by Croatian researcher Predrag Sikiric and his team at the University of Zagreb. The gastric origin is significant: gastric juice contains peptides specifically evolved to protect and repair the gut lining, and BPC-157 appears to be the active fragment responsible for much of that cytoprotective activity.
What makes BPC-157 scientifically unusual is its stability. Most peptides are rapidly destroyed by stomach acid — BPC-157 is not. It is resistant to hydrolysis in gastric juice, which is why it can be taken orally (unlike most peptides) as well as by injection. It has no sequence homology with any other known gut peptide, which makes it structurally distinctive.
The research base is simultaneously extensive and narrow. Over 30 years of published studies exist — almost entirely in rodents, almost entirely from Sikiric's group in Croatia. This single-group provenance is one of the most frequently raised concerns in critical reviews: when virtually all the data comes from one research team, independent replication is not possible, and conflicts of interest are harder to rule out.
The single-source problem: A 2026 investigative report by STAT News found that nearly all BPC-157 animal research originates from one Croatian research group. A 2015 Phase I human trial registered by the same group submitted data to clinicaltrials.gov but then withdrew it before peer review — and the results have never been published. The lead researcher declined repeated interview requests. This is important context for evaluating the literature.
BPC-157 has been studied across an unusually wide range of biological systems — gut, tendon, bone, heart, brain, liver, kidney, cornea. Critics note that a compound claimed to benefit almost everything should trigger scepticism. Supporters counter that its broad effects reflect a fundamental cytoprotective mechanism acting upstream of many specific pathologies.
No peptide has a larger community footprint than BPC-157. It was one of the first peptides to cross over from specialist biohacking forums into mainstream wellness podcasts, and the gap between community enthusiasm and clinical evidence is arguably wider here than anywhere else in this space. Andrew Huberman's 2024 podcast episode — where he used the words "cancer," "tumour," and "risk" more than three dozen times in one sitting — marked a turning point where mainstream commentary started applying more scrutiny.
The FDA classified BPC-157 as a Category 2 bulk drug substance in 2023, meaning it cannot be legally compounded by commercial US pharmacies. This forced it further into grey-market territory — online research chemical suppliers and overseas sources — with corresponding quality and purity concerns. Despite this, numerous US clinics with licensed physicians continue to offer it, exploiting regulatory grey areas around classification.
BPC-157 is one of the only peptides with well-documented efficacy across three distinct routes of administration — subcutaneous injection, intramuscular injection, and oral. The right route depends entirely on your target tissue. Systemic healing uses SubQ; specific muscle or joint injuries benefit from IM site-injection; gut issues use oral.
The compounds and practices below have evidence supporting synergy with this peptide — either working on the same biological pathway, providing essential co-factors, or creating the physiological conditions that amplify the peptide's effects. Evidence ratings reflect the strength of the supporting science.
BPC-157 is a genuinely interesting compound with a plausible mechanism and consistent preclinical findings across multiple tissue systems. The gastric origin gives the gut healing applications a particularly coherent biological basis. And the short-term human safety data that does exist — while extremely limited — is not alarming.
But the evidence situation is worse than the community typically presents. Fewer than 30 humans have been studied in published trials. The only Phase I trial never published its results. The research base is dominated by one group whose lead researcher declined all interview requests from investigative journalists. The FDA classified it as potentially unsafe for compounding. And the theoretical cancer risk from angiogenesis promotion is real, even if unquantified.
The podcast hype around BPC-157 has significantly outrun the science. That does not make it useless — but it does mean that anyone using it should do so with eyes fully open to the genuine gaps in the evidence, not in spite of them.